Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2.
Saved in:
| Title: | Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2. |
|---|---|
| Authors: | Verrillo CE; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Quaglia F; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Shields CD; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Lin S; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Kossenkov AV; Bioinformatics Shared Resource, Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania, USA., Tang HY; Proteomics and Metabolomics Shared Resource, The Wistar Institute, Philadelphia, Pennsylvania, USA., Speicher D; Proteomics and Metabolomics Shared Resource, The Wistar Institute, Philadelphia, Pennsylvania, USA., Naranjo NM; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Testa A; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Kelly WK; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Liu Q; Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA., Leiby B; Division of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Musante L; Extracellular Vesicle Core, PennVet, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Sossey-Alaoui K; Department of Medicine, Case Western Reserve University, School of Medicine MetroHealth Medical Center Rammelkamp Center for Research, Cleveland, Ohio, USA., Dogra N; Department of Pathology and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Chen TY; Department of Pathology and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Altieri DC; Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA., Languino LR; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. |
| Source: | Journal of extracellular vesicles [J Extracell Vesicles] 2024 Aug; Vol. 13 (8), pp. e12482. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101610479 Publication Model: Print Cited Medium: Internet ISSN: 2001-3078 (Electronic) Linking ISSN: 20013078 NLM ISO Abbreviation: J Extracell Vesicles Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
